Background
Methods
Initial study and 18–24 months and 5-year follow-up
Analysis
Characteristic | Preterm (<30 weeks) N = 158 women | Preterm (30–36 weeks) N = 781 women | Term (≥37 weeks) N = 437 women |
---|---|---|---|
Mean maternal age (years) (SD) | 29.3 (6.3) | 29.8 (6.2) | 28.1 (6.2) |
Treatment group | |||
Single course | 76 (48.1%) | 375 (48.0%) | 236 (54.0%) |
Repeat courses | 82 (51.5%) | 406 (52%) | 201 (46.0%) |
Multiple pregnancy | 37 (23.4%) | 244 (31.2%) | 26 (5.9%) |
Number of fetuses | |||
Singleton | 121 (77%) | 537(69%) | 411 (94%) |
Twin | 29 (18%) | 197 (25%) | 25 (6%) |
Triplet | 8 (5%) | 47 (6%) | 1 (<0.01%) |
Mean gestational age at randomization (weeks) (SD) | 27.2 (1.1) | 29.7 (1.9) | 29.6 (1.9) |
Gestational age at randomization (weeks) | |||
< 25 | 0 (0%) | 0 (0%) | 0 (0%) |
25-27 | 114 (72%) | 163 (21%) | 91 (21%) |
28-32 | 44 (28%) | 618 (79%) | 334 (79%) |
> 32 | 0 (0%) | 0 (0%) | 2 (<0.01%) |
Preterm pre-labor rupture of membranes at randomization | 77 (49%) | 138 (18%) | 8 (1.8%) |
National perinatal mortality rate of countryb
| |||
≤ 10/1000 | 127(80%) | 553 (71%) | 224 (51%) |
> 10 - 20/1000 | 22 (14%) | 187 (24%) | 175 (40%) |
> 20/1000 | 9 (6%) | 41 (5%) | 38 (9%) |
Number of previous pregnancies | |||
0 | 50 (32%) | 245 (31%) | 103 (24%) |
1-4 | 91 (57%) | 465 (60%) | 287 (66%) |
>4 | 17 (11%) | 70 (9%) | 45 (10%) |
Missing | 1 (<0.01%) | 2 (<0.01%) | |
Maternal smoking | 15 (9%) | 64 (8%) | 62 (14%) |
Number of courses of study drug | |||
0 | 2 (1.2%) | 3 (<0.01%) | 1 (<0.01%) |
1 | 128(81%) | 312 (40%) | 109 (25%) |
2 | 26 (16%) | 225 (33%) | 156 (36%) |
3 | 1 (0.1%) | 133 (17%) | 103 (24%) |
4 | 0 (0%) | 78 (10%) | 68 (16%) |
Missing | 1 (0.1%) | 0 (0%) | 0 (0%) |
Results
Study participants
Outcomes | Preterm (<30 weeks) N = 200 | Preterm (30–36 weeks) N = 1066 | Term (≥37 weeks) N = 462a
|
---|---|---|---|
Genderb
| |||
Male | 106 (53%) | 560 (53%) | 240 (52%) |
Female | 94 (47%) | 506 (47%) | 222 (48%) |
Death or serious neonatal morbidity: composite primary outcome (one or more of death, severe RDSc, BPDd, IVHe [grade III/IV], cystic PVLf, NECg) | 126 (64%) | 107 (10%) | 2 (<0.01%) |
Missing | 0 (0%) | 0 (0%) | 1 (<0.01%) |
Death or neurologic impairment at 18–24 months: composite primary outcome (one or more of death, cerebral palsy or cognitive delay) | 89 (45%) | 128 (12.0%) | 27 (6%) |
Missing | 1 (0.01%) | 5 (0.1%) | 2 (<0.01%) |
Death or severe disability (neuromotor, neurosensory, neurocognitive) at 5 years § | 104 (52%) | 237 (22%) | 86 (19%) |
Outcome
Preterm (<30 weeks) N = 200 | Preterm (30–36 weeks) N = 1066 | Term (≥37 weeks) N = 462 | ||||
---|---|---|---|---|---|---|
Outcome | Multiple ACS N = 105 | Single ACS N = 95 | Multiple ACS N = 553 | Single ACS N = 504 | Multiple ACS N = 213a
| Single ACS N = 249 |
Death or severe disability (neuromotor, neurosensory, neurocognitive)§ | 54/105 (51.4%) | 50/95 (52.6%) | 115/553 (20.8%) | 122/504 (24.2%) | 48/213 (22.5%) | 38/249 (15.3%) |
Death up to 5 years | 29/105 (27.6%) | 23/95 (24.2%) | 16/555 (2.9%) | 22/511 (4.3%) | 1/213 (0.5%) | 2/249 (0.8%) |
Neuromotor disability †† (non-ambulatory cerebral palsy) | 1/76 (1.3%) | 6/72 (8.3%) | 3/539 (0.6%) | 4/489 (0.8%) | 0/212 (0%) | 1/247 (0.4%) |
Neurosensory disability | 13/76 (17.1%) | 13/72 (18.1%) | 38/539 (7.1%) | 41/489 (8.4%) | 19/212 (9.0%) | 7/247 (2.8%) |
Needing visual aids | 9/76 (11.8%) | 11/72 (15.3%) | 35/539 (6.5%) | 34/489 (7.0%) | 17/212 (8.0%) | 7/247 (2.8%) |
Deafness | 4/76 (5.3%) | 2/72 (2.8%) | 4/539 (0.7%) | 3/489 (0.6%) | 3/212 (1.4%) | 1/247 (0.4%) |
Pre-existing (diagnosed at 2 years or earlier) | 3 | 2 | 1 | 2 | 0 | 0 |
New (diagnosed after 2 years of age) | 1 | 0 | 3 | 1 | 3 | 1 |
Neurocognitive/neurobehavioural disability | 15/76 (19.7%) | 16/69 (23.2%) | 62/534 (11.6%) | 63/478 (13.2%) | 31/212 (14.6%) | 30/246 (12.2%) |
Death or severe disability | |||
---|---|---|---|
Covariate | Comparison | OR [ 95% confidence limits] |
p-value |
Gestational age at randomization | 26-27 vs. 28+ weeks | 1.02 [0.76, 1.38] | 0.897 |
Premature rupture of membranes | Yes vs. No | 1.58 [1.14, 2.18] | 0.009 |
Mother smokes | Yes vs. No | 1.62 [1.10, 2.40] | 0.023 |
Parity | 1+ vs. 0 | 1.26 [1.02, 1.56] | 0.033 |
Country PMRa
| >10/1000 vs. ≤10/1000 | 1.33 [1.09, 1.61] | 0.006 |
Neurosensory disability
| |||
Covariate
|
Comparison
|
OR [ 95% confidence limits]
|
p
-value
|
Gestational age at randomization | 26-27 vs. 28+ weeks | 1.04 [0.67, 1.60] | 0.877 |
Premature rupture of membranes | Yes vs. No | 1.58 [0.94, 2.64] | 0.110 |
Neurocognitive
| |||
Gestational age at randomization | 26-27 vs. 28+ weeks | 0.94 [0.64, 1.40] | 0.764 |
Multiple pregnancy | Yes vs. No | 0.60 [0.41, 0.89] | 0.006 |
Maternal smoking | Yes vs. No | 2.18 [1.44, 3.31] | 0.002 |
Sex of the baby | Male vs. Female | 1.65 [1.23, 2.20] | 0.001 |
Country PMRa
| >10/1000 vs. ≤10/1000 | 1.40 [1.10, 1.78] | 0.012 |
Death
| |||
Gestational age at randomization | 26-27 vs. 28+ weeks | 1.42 [0.84, 2.40] | 0.1984 |
Premature rupture of membranes | Yes vs. No | 2.08 [1.27, 3.41] | 0.0089 |
parity | 1+ vs. 0 | 1.44 [0.98, 2.11] | 0.0700 |
Country PMRa
| >10/1000 vs. ≤10/1000 | 2.37 [1.69, 3.33] | 0.0001 |
Outcome | Gestational age at birth | OR [ 95% confidence limits] |
p-value |
p-value for interaction |
---|---|---|---|---|
Death or severe disabilitya
| < 30 weeks | 0.85 [0.35, 2.11] | 0.608 | 0.064 |
30-36 weeks | 0.84 [0.52, 1.36] | 0.262 | ||
≥ 37 weeks
|
1.69 [1.04, 2.77]
|
0.037*
| ||
Neurosensory disabilityb
| < 30 weeks | 0.85 [0.35, 2.11] | 0.732 | 0.021 |
30-36 weeks | 0.84 [0.52, 1.36] | 0.481 | ||
≥ 37 weeks
|
3.70 [1.57, 8.75]
|
0.004*
| ||
Neurocognitivec
| < 30 weeks | 0.84 [0.35, 2.01] | 0.698 | 0.605 |
30-36 weeks | 0.91 [0.61, 1.36] | 0.632 | ||
≥ 37 weeks | 1.31 [0.75, 2.29] | 0.347 | ||
Deathd
| < 30 weeks | 1.10 [0.54, 2.24] | 0.794 | 0.587 |
30-36 weeks | 0.68 [0.35, 1.31] | 0.247 | ||
≥ 37 weeks | sparse data, no convergence |
Outcome | Gestational age at birth | OR |
---|---|---|
Death or severe disability | < 30 weeks | 0.92 |
30-36 weeks | 0.83 | |
≥ 37 weeks | 1.64 | |
Neurosensory disability | < 30 weeks | 0.90 |
30-36 weeks | 0.81 | |
≥ 37 weeks | 3.48 | |
Neurocognitive | < 30 weeks | 0.76 |
30-36 weeks | 0.90 | |
≥ 37 weeks | 1.30 | |
Death | < 30 weeks | 1.19 |
30-36 weeks | 0.66 | |
≥ 37 weeks | 0.58 |